(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
J&J’s Monarch Robotic System Gains FDA Clearance for AI-Powered Lung Cancer Diagnosis
Johnson & Johnson’s Monarch robotic lung biopsy system has received FDA 510(k) clearance for its Monarch Quest software, designed to improve accuracy in detecting lung cancer. The update boosts computational power by 260% using NVIDIA’s AI platform and integrates GE Healthcare’s OEC 3D imaging system to enhance real-time navigation.
Lung cancer has one of the lowest five-year survival rates, often due to late diagnosis. Since nearly half of early-stage tumors reside in hard-to-reach peripheral lung areas, Monarch helps physicians navigate deeper into the lungs for more precise biopsies. The software upgrade extends AI capabilities from preoperative planning to intraoperative navigation and post-operative analysis, potentially improving early detection and patient outcomes.
J&J acquired Monarch in 2019 through its $3.4 billion Auris Health acquisition and is also developing Ottava, a soft-tissue surgical robot, to compete with Intuitive Surgical’s da Vinci system.
18-03-2025